Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109811 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00109811: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00109811 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109811, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL PSA:154-163(155L) peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109811
The ClinicalTrials.gov registry entry for NCT00109811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00109811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109811 about?
NCT00109811 is a clinical study titled "Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer". This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
What is the current status of trial NCT00109811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-03.
What interventions are being tested in trial NCT00109811?
The interventions under investigation include: laboratory biomarker analysis (OTHER), incomplete Freund's adjuvant (BIOLOGICAL), PSA:154-163(155L) peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109811?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.